Search Results

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

• Authors : Mease, Philip; Mozaffarian, Neelufar; Greer, Joy M.

Subjects: ANTIRHEUMATIC agents; COMBINATION drug therapy; COMPARATIVE studies

• Source: Lancet. 12/1/2018, Vol. 392 Issue 10162, p2367-2377. 9p.

Record details

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.

• Authors : Simpson, E.L.; Lacour, J.‐P.; Spelman, L.

Subjects: ATOPIC dermatitis; PATIENT safety; CARDIOVASCULAR diseases

• Source: British Journal of Dermatology; Aug2020, Vol. 183 Issue 2, p242-255, 14p

Record details

Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study.

• Authors : Piraccini, B. M.^1,2 (AUTHOR); Pampaloni, F.^1,2 (AUTHOR) ; Cedirian, S.^1,2 (AUTHOR)

Subjects: *JANUS kinases; *ALOPECIA areata; *BALDNESS

• Source: Journal of the European Academy of Dermatology & Venereology. Sep2024, p1. 9p. 5 Illustrations.

Record details

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis.

• Authors : Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong

Subjects: BIOMARKERS; C-reactive protein; CYTOKINES

• Source: Journal of Clinical Pharmacology. Apr2018, Vol. 58 Issue 4, p434-447. 14p.

Record details

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.

• Authors : Wang, Ellen Q.; Le, Vu; O'Gorman, Melissa

Subjects: EXPERIMENTAL design; CONFIDENCE intervals; DRUG toleranceUNITED States

• Source: Journal of Clinical Pharmacology; Oct2021, Vol. 61 Issue 10, p1311-1323, 13p

Record details

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.

• Authors : Srinivas, Nithya; Barbour, April M.; Epstein, Noam

Subjects: ANTINEOPLASTIC agents; CONFIDENCE intervals; GRAFT versus host disease

• Source: Journal of Clinical Pharmacology; Aug2020, Vol. 60 Issue 8, p1022-1029, 8p

Record details

Education Full Text (H.W. Wilson)

Record details

Study Finds JAK Inhibitors Safer Than Other Systemic Agents.

• Authors : Bader, Kaitlyn

Subjects: EVALUATION of medical care; JANUS kinases; UNITED States. Food & Drug Administration

• Source: Dermatology Times. Jan2023, Vol. 44 Issue 1, p16-17. 2p.

Record details

Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.

• Authors : Hu, Wilson¹ ; Thornton, Michele¹; Livingston, Robert A.¹

Subjects: *PAIN; *JANUS kinases; *ATOPIC dermatitis

• Source: American Journal of Clinical Dermatology. Mar2024, Vol. 25 Issue 2, p327-332. 6p.

Record details

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.

• Authors : Mohamed, Mohamed‐Eslam F.; Trueman, Sheryl; Feng, Tian

Subjects: ANALYSIS of covariance; CONFIDENCE intervals; GLOMERULAR filtration rate

• Source: Journal of Clinical Pharmacology; Jun2019, Vol. 59 Issue 6, p856-862, 7p

Record details